BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32855439)

  • 1. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia.
    Roeker LE; Knorr DA; Pessin MS; Ramanathan LV; Thompson MC; Leslie LA; Zelenetz AD; Mato AR
    Leukemia; 2020 Nov; 34(11):3047-3049. PubMed ID: 32855439
    [No Abstract]   [Full Text] [Related]  

  • 2. Recovered COVID-19 patients with recurrent viral RNA exhibit lower levels of anti-RBD antibodies.
    Liu B; Shi Y; Zhang W; Li R; He Z; Yang X; Pan Y; Deng X; Tan M; Zhao L; Zou F; Zhang Y; Pan T; Zhang J; Zhang X; Xiao F; Li F; Deng K; Zhang H
    Cell Mol Immunol; 2020 Oct; 17(10):1098-1100. PubMed ID: 32939033
    [No Abstract]   [Full Text] [Related]  

  • 3. Mining of epitopes on spike protein of SARS-CoV-2 from COVID-19 patients.
    Zhang BZ; Hu YF; Chen LL; Yau T; Tong YG; Hu JC; Cai JP; Chan KH; Dou Y; Deng J; Wang XL; Hung IF; To KK; Yuen KY; Huang JD
    Cell Res; 2020 Aug; 30(8):702-704. PubMed ID: 32612199
    [No Abstract]   [Full Text] [Related]  

  • 4. Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection.
    Lin Q; Zhu L; Ni Z; Meng H; You L
    J Microbiol Immunol Infect; 2020 Oct; 53(5):821-822. PubMed ID: 32249185
    [No Abstract]   [Full Text] [Related]  

  • 5. A COVID-19 Patient with Repeatedly Undetectable SARS-CoV-2 Antibodies.
    Goetz L; Yang J; Greene W; Zhu Y
    J Appl Lab Med; 2020 Nov; 5(6):1401-1405. PubMed ID: 32745181
    [No Abstract]   [Full Text] [Related]  

  • 6. Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients.
    Varnaitė R; García M; Glans H; Maleki KT; Sandberg JT; Tynell J; Christ W; Lagerqvist N; Asgeirsson H; Ljunggren HG; Ahlén G; Frelin L; Sällberg M; Blom K; Klingström J; Gredmark-Russ S
    J Immunol; 2020 Nov; 205(9):2437-2446. PubMed ID: 32878912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluations of the serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak.
    Lin D; Liu L; Zhang M; Hu Y; Yang Q; Guo J; Dai Y; Xu Y; Cai Y; Chen X; Huang K; Zhang Z
    Eur J Clin Microbiol Infect Dis; 2020 Dec; 39(12):2271-2277. PubMed ID: 32681308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity.
    Ripperger TJ; Uhrlaub JL; Watanabe M; Wong R; Castaneda Y; Pizzato HA; Thompson MR; Bradshaw C; Weinkauf CC; Bime C; Erickson HL; Knox K; Bixby B; Parthasarathy S; Chaudhary S; Natt B; Cristan E; El Aini T; Rischard F; Campion J; Chopra M; Insel M; Sam A; Knepler JL; Capaldi AP; Spier CM; Dake MD; Edwards T; Kaplan ME; Scott SJ; Hypes C; Mosier J; Harris DT; LaFleur BJ; Sprissler R; Nikolich-Žugich J; Bhattacharya D
    Immunity; 2020 Nov; 53(5):925-933.e4. PubMed ID: 33129373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic changes in virology, specific antibody response and imaging during the clinical course of COVID-19: a descriptive study.
    Wang QJ; Yao YZ; Song JS; Wang Q; Xu LY; Bao ZJ; Mao DW; Zhou JH; Zhang ZE; Wang Y; Li YW; Wang HP; Li L; Pan HY; Zhang GQ; Li SB
    BMC Infect Dis; 2020 Nov; 20(1):818. PubMed ID: 33167900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct Early Serological Signatures Track with SARS-CoV-2 Survival.
    Atyeo C; Fischinger S; Zohar T; Slein MD; Burke J; Loos C; McCulloch DJ; Newman KL; Wolf C; Yu J; Shuey K; Feldman J; Hauser BM; Caradonna T; Schmidt AG; Suscovich TJ; Linde C; Cai Y; Barouch D; Ryan ET; Charles RC; Lauffenburger D; Chu H; Alter G
    Immunity; 2020 Sep; 53(3):524-532.e4. PubMed ID: 32783920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low prevalence of IgG antibodies to SARS-CoV-2 in cancer patients with COVID-19.
    Liu T; Zeng G; Tao H; Shi Y; ; Wang T; Liu T; Guo F; Zhou F; Wang X
    Int J Cancer; 2020 Dec; 147(11):3267-3269. PubMed ID: 32525566
    [No Abstract]   [Full Text] [Related]  

  • 12. Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate.
    Addetia A; Crawford KHD; Dingens A; Zhu H; Roychoudhury P; Huang ML; Jerome KR; Bloom JD; Greninger AL
    J Clin Microbiol; 2020 Oct; 58(11):. PubMed ID: 32826322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma.
    Yasuda H; Tsukune Y; Watanabe N; Sugimoto K; Uchimura A; Tateyama M; Miyashita Y; Ochi Y; Komatsu N
    Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):774-776. PubMed ID: 32933879
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders.
    Marklund E; Leach S; Axelsson H; Nyström K; Norder H; Bemark M; Angeletti D; Lundgren A; Nilsson S; Andersson LM; Yilmaz A; Lindh M; Liljeqvist JÅ; Gisslén M
    PLoS One; 2020; 15(10):e0241104. PubMed ID: 33085715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular immune responses to covid-19.
    Sewell HF; Agius RM; Stewart M; Kendrick D
    BMJ; 2020 Jul; 370():m3018. PubMed ID: 32737031
    [No Abstract]   [Full Text] [Related]  

  • 16. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019.
    Burbelo PD; Riedo FX; Morishima C; Rawlings S; Smith D; Das S; Strich JR; Chertow DS; Davey RT; Cohen JI
    J Infect Dis; 2020 Jun; 222(2):206-213. PubMed ID: 32427334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accurate serology for SARS-CoV-2 and common human coronaviruses using a multiplex approach.
    van Tol S; Mögling R; Li W; Godeke GJ; Swart A; Bergmans B; Brandenburg A; Kremer K; Murk JL; van Beek J; Wintermans B; Reimerink J; Bosch BJ; Reusken C
    Emerg Microbes Infect; 2020 Dec; 9(1):1965-1973. PubMed ID: 32819220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients.
    Deshpande GR; Sapkal GN; Tilekar BN; Yadav PD; Gurav Y; Gaikwad S; Kaushal H; Deshpande KS; Kaduskar O; Sarkale P; Baradkar S; Suryawanshi A; Lakra R; Sugunan AP; Balakrishnan A; Abraham P; Salve P
    Indian J Med Res; 2020 Jul & Aug; 152(1 & 2):82-87. PubMed ID: 32859866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients.
    Choe PG; Kang CK; Suh HJ; Jung J; Kang E; Lee SY; Song KH; Kim HB; Kim NJ; Park WB; Kim ES; Oh MD
    Emerg Infect Dis; 2020 Oct; 26(10):2484-2487. PubMed ID: 32579877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.